{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:27:24Z","timestamp":1778275644203,"version":"3.51.4"},"reference-count":151,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1231521N"],"award-info":[{"award-number":["1231521N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>Spondyloarthritis (SpA) is a family of inflammatory arthritic diseases, which includes the prototypes of psoriatic arthritis and ankylosing spondylitis. SpA is commonly associated with systemic inflammatory diseases, such as psoriasis and inflammatory bowel disease. Immunological studies, murine models and the genetics of SpA all indicate a pathogenic role for the IL-23\/IL-17 axis. Therapeutics targeting the IL-23\/IL-17 pathway are successful at providing symptomatic relief, but may not provide complete protection against progression of arthritis. Thus there is still tremendous interest in the discovery of novel therapeutic targets for SpA. Tyrosine kinase 2 (TYK2) is a member of the Janus kinases, which mediate intracellular signaling of cytokines via signal transducer and activator of transcription (STAT) activation. TYK2 plays a crucial role in mediating IL-23 receptor signaling and STAT3 activation. A plethora of natural mutations in and around TYK2 have provided a wealth of data to associate this kinase with autoimmune\/autoinflammatory diseases in humans. Induced and natural mutations in murine Tyk2 largely support human data; however, key inter-species differences exist, which means extrapolation of data from murine models to humans needs to be done with caution. Despite these reservations, novel selective TYK2 inhibitors are now proving successful in advanced clinical trials of inflammatory diseases. In this review, we will discuss TYK2 from basic biology to therapeutic targeting, with an emphasis on studies in SpA. Seminal studies uncovering the basic science of TYK2 have provided sound foundations for targeting it in SpA and related inflammatory diseases. TYK2 inhibitors may well be the next blockbuster therapeutic for SpA.<\/jats:p>","DOI":"10.3389\/fgene.2021.685280","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T06:35:47Z","timestamp":1625466947000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases"],"prefix":"10.3389","volume":"12","author":[{"given":"Dominika","family":"Hromadov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Elewaut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert D.","family":"Inman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Strobl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Gracey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/S2665-9913(19)30008-6","article-title":"Precision medicine in psoriatic arthritis: how should we select targeted therapies?","volume":"1","author":"Al-Mossawi","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK\u2013STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects.","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/jcph.1046","article-title":"The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2\/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis.","volume":"58","author":"Banfield","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau8714","article-title":"Tuberculosis and impaired IL-23\u2013dependent IFN- immunity in humans homozygous for a common TYK2 missense variant.","volume":"3","author":"Boisson-Dupuis","year":"2018","journal-title":"Sci. Immunol."},{"key":"B6","article-title":"Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis.","volume":"6","author":"Bowes","year":"2015","journal-title":"Nat. Commun."},{"key":"B7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-immunol-032414-112110","article-title":"HLA-B27.","volume":"33","author":"Bowness","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"B8","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nprot.2007.173","article-title":"Collagen-induced arthritis.","volume":"2","author":"Brand","year":"2007","journal-title":"Nat. Protoc."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.","volume":"76","author":"Braun","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B10","year":"2021","journal-title":"In the Pipeline."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain.","volume":"11","author":"Burke","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/jcb.24647","article-title":"Eliminative signaling by janus kinases: role in the downregulation of associated receptors.","volume":"115","author":"Carbone","year":"2014","journal-title":"J. Cell. Biochem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"8137","DOI":"10.1073\/pnas.0600666103","article-title":"Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells.","volume":"103","author":"Chen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08605-3","article-title":"Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation.","volume":"10","author":"Cho","year":"2019","journal-title":"Nat. Commun."},{"key":"B15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of janus kinase inhibitor selectivity.","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6508","DOI":"10.1128\/mcb.17.11.6508","article-title":"STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation.","volume":"17","author":"Chung","year":"1997","journal-title":"Mol. Cell. Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1111\/dom.14104","article-title":"Preclinical evaluation of tyrosine kinase 2 inhibitors for human beta-cell protection in type 1 diabetes.","volume":"22","author":"Coomans, de Brach\u00e8ne","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/ng.2667","article-title":"Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci.","volume":"45","author":"Cortes","year":"2013","journal-title":"Nat. Genet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002341","article-title":"Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus.","volume":"7","author":"Cunninghame Graham","year":"2011","journal-title":"PLoS Genet."},{"key":"B21","doi-asserted-by":"crossref","first-page":"363ra149","DOI":"10.1126\/scitranslmed.aag1974","article-title":"Resolving TYK2 locus genotype-To-phenotype differences in autoimmunity.","volume":"8","author":"Dendrou","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"B22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis.","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B23","article-title":"Tofacitinib for the treatment of adult patients with ankylosing spondylitis: primary analysis of a phase 3, randomized, double-blind, placebo-controlled study","author":"Deodhar","year":"2020","journal-title":"Proceedings of the ACR Meeting"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122271","article-title":"TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits.","volume":"10","author":"Diogo","year":"2015","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/rheumatology\/key267","article-title":"Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease.","volume":"58","author":"Dubash","year":"2018","journal-title":"Rheumatology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.tips.2019.03.001","article-title":"Targeting SOCS proteins to control JAK-STAT signalling in disease.","volume":"40","author":"Durham","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1212\/wnl.0b013e3182616fc4","article-title":"Exome sequencing identifies a novel multiple sclerosis susceptibility variant in the TYK2 gene.","volume":"79","author":"Dyment","year":"2012","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/ng.3528","article-title":"Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci.","volume":"48","author":"Ellinghaus","year":"2016","journal-title":"Nat. Genet."},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-25282-2","article-title":"The psoriasis-protective TYK2 I684S variant impairs IL-12 stimulated pSTAT4 response in skin-homing CD4+ and CD8+ memory T-cells.","volume":"8","author":"Enerb\u00e4ck","year":"2018","journal-title":"Sci. Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature13835","article-title":"Genetic and epigenetic fine mapping of causal autoimmune disease variants.","volume":"518","author":"Farh","year":"2015","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/s0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn\u2019s disease: a randomised, double-blind, placebo-controlled phase 2 study.","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease.","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841).","volume":"61","author":"Fensome","year":"2018","journal-title":"J. Med. Chem."},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2017.00071","article-title":"The Janus Kinase (JAK) FERM and SH2 domains: bringing specificity to JAK-receptor interactions.","volume":"8","author":"Ferrao","year":"2017","journal-title":"Front. Endocrinol."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/cells9102184","article-title":"IL-12 and IL-23-close relatives with structural homologies but distinct immunological functions.","volume":"9","author":"Floss","year":"2020","journal-title":"Cells"},{"key":"B36","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"TYK2\/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase iia, randomized, double-blind, placebo-controlled trial.","volume":"140","author":"Forman","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"B37","doi-asserted-by":"crossref","first-page":"iv79","DOI":"10.1093\/rheumatology\/keaa435","article-title":"Treatment strategies in axial spondyloarthritis: what, when and how?","volume":"59","author":"Fragoulis","year":"2020","journal-title":"Rheumatology"},{"key":"B38","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/ng.717","article-title":"Genome-wide meta-analysis increases to 71 the number of confirmed Crohn\u2019s disease susceptibility loci.","volume":"42","author":"Franke","year":"2010","journal-title":"Nat. Genet."},{"key":"B39","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","article-title":"Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.","volume":"184","author":"Fridman","year":"2010","journal-title":"J. Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1002\/eji.201646519","article-title":"Tyrosine kinase 2 is not limiting human antiviral type III interferon responses.","volume":"46","author":"Fuchs","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/nbt0113-3","article-title":"Pfizer\u2019s first-in-class JAK inhibitor pricey for rheumatoid arthritis market.","volume":"31","author":"Garber","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"B42","doi-asserted-by":"crossref","first-page":"13561","DOI":"10.1021\/acs.jmedchem.0c00948","article-title":"Discovery of tyrosine kinase 2 (TYK2) inhibitor (PF-06826647) for the treatment of autoimmune diseases.","volume":"63","author":"Gerstenberger","year":"","journal-title":"J. Med. Chem."},{"key":"B43","article-title":"Demonstration of in vitro to in vivo translation of a TYK2 inhibitor that shows cross species potency differences.","volume":"10","author":"Gerstenberger","year":"","journal-title":"Sci. Rep."},{"key":"B44","article-title":"BMS-986165 is a highly potent and selective allosteric inhibitor of Tyk2, Blocks IL-12, IL-23 and Type I interferon signaling and provides for robust efficacy in preclinical models of systemic lupus erythematosus and inflammatory bowel disease","author":"Gillooly","year":"2016","journal-title":"Proceedings of the ACR Meeting"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/nejmoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors.","volume":"377","author":"Gladman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1172\/jci126567","article-title":"TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis.","volume":"130","author":"Gracey","year":"","journal-title":"J. Clin. Invest."},{"key":"B47","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41584-020-0454-9","article-title":"Revisiting the gut\u2013joint axis: links between gut inflammation and spondyloarthritis.","volume":"16","author":"Gracey","year":"","journal-title":"Nat. Rev. Rheumatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/art.41129","article-title":"Altered cytotoxicity profile of CD8+ T cells in ankylosing spondylitis.","volume":"72","author":"Gracey","year":"","journal-title":"Arthritis Rheumatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/rheumatology\/kel449","article-title":"Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families.","volume":"46","author":"Graham","year":"2007","journal-title":"Rheumatology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.bcp.2006.04.013","article-title":"Jaks and cytokine receptors-an intimate relationship.","volume":"72","author":"Haan","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1136\/ard.2004.023176","article-title":"Open label trial of anakinra in active ankylosing spondylitis over 24 weeks.","volume":"64","author":"Haibel","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/s0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial.","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"B53","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor \u03b1 inhibitors on radiographic progression in ankylosing spondylitis.","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B54","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/13543776.2019.1567713","article-title":"Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015\u20132018).","volume":"29","author":"He","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.3899\/jrheum.081160","article-title":"Evidence for genetic association and interaction between the TYK2 and IRF5 genes in systemic lupus erythematosus.","volume":"36","author":"Hellquist","year":"2009","journal-title":"J. Rheumatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial.","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"B57","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.immuni.2020.09.015","article-title":"Second-strand synthesis-based massively parallel scRNA-Seq reveals cellular states and molecular features of human inflammatory skin pathologies.","volume":"53","author":"Hughes","year":"2020","journal-title":"Immunity"},{"key":"B58","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4049\/jimmunol.1003244","article-title":"Involvement of tyrosine kinase-2 in both the IL-12\/Th1 and IL-23\/Th17 axes in Vivo.","volume":"187","author":"Ishizaki","year":"2011","journal-title":"J. Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/intimm\/dxt062","article-title":"Tyk2 is a therapeutic target for psoriasis-like skin inflammation.","volume":"26","author":"Ishizaki","year":"2014","journal-title":"Int. Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/annrheumdis-2016-209853","article-title":"Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis.","volume":"76","author":"Jadon","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"12530","DOI":"10.1074\/jbc.m010074200","article-title":"The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2.","volume":"276","author":"Kamizono","year":"2001","journal-title":"J. Biol. Chem."},{"key":"B62","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/s1074-7613(00)00054-6","article-title":"Partial impairment of cytokine responses in Tyk2-deficient mice.","volume":"13","author":"Karaghiosoff","year":"2000","journal-title":"Immunity"},{"key":"B63","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/ijd.14246","article-title":"Review of safety and efficacy of approved systemic psoriasis therapies.","volume":"58","author":"Kaushik","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"10430","DOI":"10.1073\/pnas.1903561116","article-title":"Homozygosity for TYK2 P1104A underlies tuberculosis in about 1% of patients in a cohort of European ancestry.","volume":"116","author":"Kerner","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2019-216741","article-title":"Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence.","volume":"79","author":"Koo","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B66","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1084\/jem.20140280","article-title":"Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome.","volume":"212","author":"Kreins","year":"2015","journal-title":"J. Exp. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"18566","DOI":"10.1074\/jbc.m800991200","article-title":"Basal ubiquitin-independent internalization of interferon \u03b1 receptor is prevented by Tyk2-mediated masking of a linear endocytic motif.","volume":"283","author":"Kumar","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.4049\/jimmunol.1203118","article-title":"Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent.","volume":"190","author":"Li","year":"2013","journal-title":"J. Immunol."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225289","article-title":"Two common disease-associated TYK2 variants impact exon splicing and TYK2 dosage.","volume":"15","author":"Li","year":"2020","journal-title":"PLoS One"},{"key":"B70","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-04013-1","article-title":"The molecular basis of JAK\/STAT inhibition by SOCS1.","volume":"9","author":"Liau","year":"2018","journal-title":"Nat. Commun."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1136\/annrheumdis-2020-217092","article-title":"Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020.","volume":"79","author":"Lortholary","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"8025","DOI":"10.1073\/pnas.1401180111","article-title":"Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.","volume":"111","author":"Lupardus","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B73","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1101\/gr.6.9.846","article-title":"Comparative analysis of 1196 orthologous mouse and human full-length mRNA and protein sequences.","volume":"6","author":"Maka\u0142owski","year":"1996","journal-title":"Genome Res."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000592","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.","volume":"3","author":"Marzo-Ortega","year":"2017","journal-title":"RMD Open"},{"key":"B75","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.614255","article-title":"Why inhibition of IL-23 lacked efficacy in ankylosing spondylitis.","volume":"12","author":"McGonagle","year":"2021","journal-title":"Front. Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.","volume":"80","author":"Mease","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B77","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.","volume":"395","author":"Mease","year":"","journal-title":"Lancet"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/s0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.","volume":"392","author":"Mease","year":"","journal-title":"Lancet"},{"key":"B79","article-title":"Efficacy and safety of deucravacitinib (BMS-986165), an oral, selective tyrosine Kinase 2 inhibitor, in patients with active psoriatic arthritis: results from a Phase 2, randomized, double-blind, placebo-controlled trial","author":"Mease","year":"2020","journal-title":"Proceedings of the ACR Meeting"},{"key":"B80","first-page":"890","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.","volume":"77","author":"Mease","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B81","doi-asserted-by":"publisher","first-page":"449","DOI":"10.4155\/ppa.14.23","article-title":"Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases.","volume":"3","author":"Menet","year":"2014","journal-title":"Pharm. Pat. Anal."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: differences between mouse and human immunology.","volume":"172","author":"Mestas","year":"2004","journal-title":"J. Immunol."},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.","volume":"7","author":"Meyer","year":"2010","journal-title":"J. Inflamm."},{"key":"B84","article-title":"Potent and selective Tyk2 inhibitors Block Th1- and Th17- mediated immune responses and reduce disease progression in rodent models of delayed-type hypersensitivity and psoriasis","author":"Miao","year":"2015","journal-title":"Proceedings of the ACR Meeting"},{"key":"B85","article-title":"Potent and selective Tyk2 inhibitor highly efficacious in rodent models of inflammatory bowel disease and psoriasis","author":"Miao","year":"2016","journal-title":"Proceedings of the ACR Meeting"},{"key":"B86","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.immuni.2006.09.009","article-title":"Human tyrosine Kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity.","volume":"25","author":"Minegishi","year":"2006","journal-title":"Immunity"},{"key":"B87","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15912-6","article-title":"TYK2-induced phosphorylation of Y640 suppresses STAT3 transcriptional activity.","volume":"7","author":"Mori","year":"2017","journal-title":"Sci. Rep."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway.","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1136\/annrheumdis-2019-215062","article-title":"Identification of rare coding variants in TYK2 protective for rheumatoid arthritis in the Japanese population and their effects on cytokine signalling.","volume":"78","author":"Motegi","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1074\/jbc.274.4.1875","article-title":"Identification of a STAT4 binding site in the interleukin-12 receptor required for signaling.","volume":"274","author":"Naeger","year":"1999","journal-title":"J. Biol. Chem."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.4049\/jimmunol.181.3.2071","article-title":"Tyk2-signaling plays an important role in host defense against Escherichia coli through IL-23-Induced IL-17 production by \u03b3\u03b4 T Cells.","volume":"181","author":"Nakamura","year":"2008","journal-title":"J. Immunol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.","volume":"80","author":"Nash","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B93","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1073\/pnas.051611498","article-title":"Estimation of divergence times from multiprotein sequences for a few mammalian species and several distantly related organisms.","volume":"98","author":"Nei","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B94","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-25260-8","article-title":"Compound heterozygous TYK2 mutations underlie primary immunodeficiency with T-cell lymphopenia.","volume":"8","author":"Nemoto","year":"2018","journal-title":"Sci. Rep."},{"key":"B95","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention.","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"B96","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","article-title":"Treatment guidelines in psoriatic arthritis.","volume":"59","author":"Ogdie","year":"2020","journal-title":"Rheumatology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials.","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"key":"B98","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.","volume":"376","author":"Papp","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.","volume":"74","author":"Papp","year":"","journal-title":"J. Am. Acad. Dermatol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.","volume":"174","author":"Papp","year":"","journal-title":"Br. J. Dermatol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/nejmoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis.","volume":"379","author":"Papp","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.","volume":"6","author":"Park","year":"2005","journal-title":"Nat. Immunol."},{"key":"B103","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/ni.3579","article-title":"Regulation of autoantibody activity by the IL-23\u2013TH17 axis determines the onset of autoimmune disease.","volume":"18","author":"Pfeifle","year":"2017","journal-title":"Nat. Immunol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"33811","DOI":"10.1074\/jbc.m111.270207","article-title":"Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon \u03b1 receptor (IFNAR1)-associated tyrosine kinase tyk2.","volume":"286","author":"Piganis","year":"2011","journal-title":"J. Biol. Chem."},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039141","article-title":"TYK2 kinase activity is required for functional type I interferon responses in Vivo.","volume":"7","author":"Prchal-Murphy","year":"2012","journal-title":"PLoS One"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2015.1047579","article-title":"In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity.","volume":"4","author":"Prchal-Murphy","year":"2015","journal-title":"Oncoimmunology"},{"key":"B108","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/emboj\/cdg038","article-title":"The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression.","volume":"22","author":"Ragimbeau","year":"2003","journal-title":"EMBO J."},{"key":"B109","doi-asserted-by":"publisher","first-page":"32507","DOI":"10.1074\/jbc.274.45.32507","article-title":"Catalytically active TYK2 is essential for interferon-\u03b2-mediated phosphorylation of STAT3 and interferon-\u03b1 receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase.","volume":"274","author":"Rani","year":"1999","journal-title":"J. Biol. Chem."},{"key":"B110","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/s0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"B111","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic Arthritis.","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general.","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"B113","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis.","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B114","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/art.41667","article-title":"TNF inhibitors reduce spinal radiographic progression in patients with radiographic axial spondyloarthritis: a longitudinal analysis from the ALBERTA FORCAST cohort.","volume":"73","author":"Sepriano","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"11594","DOI":"10.1073\/pnas.1930781100","article-title":"A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q\/J mice to infection and autoimmunity.","volume":"100","author":"Shaw","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B117","doi-asserted-by":"publisher","first-page":"7263","DOI":"10.4049\/jimmunol.176.12.7263","article-title":"Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFN-\u03b3-dependent IL-10 reactivation.","volume":"176","author":"Shaw","year":"2006","journal-title":"J. Immunol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/s1074-7613(00)00055-8","article-title":"Tyk2 plays a restricted role in IFN\u03b1 signaling, although it is required for IL-12-mediated T cell function.","volume":"13","author":"Shimoda","year":"2000","journal-title":"Immunity"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1136\/annrheumdis-2018-213654","article-title":"Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?","volume":"78","author":"Siebert","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1136\/annrheumdis-2013-204963","article-title":"Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN).","volume":"74","author":"Sieper","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"B121","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","article-title":"The assessment of spondyloarthritis international society (ASAS) handbook: a guide to assess spondyloarthritis.","volume":"68","author":"Sieper","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"B122","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1086\/428480","article-title":"Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus.","volume":"76","author":"Sigurdsson","year":"2005","journal-title":"Am. J. Hum. Genet."},{"key":"B123","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/annrheumdis-2016-209831","article-title":"A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate.","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1126\/science.7871433","article-title":"Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors.","volume":"267","author":"Stahl","year":"1995","journal-title":"Science"},{"key":"B125","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/art.41156","article-title":"Polyfunctional, proinflammatory, tissue-resident memory phenotype and function of synovial interleukin-17A+CD8+ T cells in psoriatic arthritis.","volume":"72","author":"Steel","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/ng.694","article-title":"A genome-wide asociation study identifies new psoriasis susceptibility loci and an interaction betwEn HLA-C and ERAP1.","volume":"42","author":"Strange","year":"2010","journal-title":"Nat. Genet."},{"key":"B127","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ajhg.2015.10.019","article-title":"Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture.","volume":"97","author":"Stuart","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"B128","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41584-018-0044-2","article-title":"IL-17 in the immunopathogenesis of spondyloarthritis.","volume":"14","author":"Taams","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"B129","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis.","volume":"374","author":"Taurog","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B130","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study.","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B131","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/cts.12929","article-title":"Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study.","volume":"3","author":"Tehlirian","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.","volume":"21","author":"Teng","year":"2015","journal-title":"Nat. Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"11061","DOI":"10.1074\/jbc.m114.619502","article-title":"Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain.","volume":"290","author":"Tokarski","year":"2015","journal-title":"J. Biol. Chem."},{"key":"B134","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-Induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis.","volume":"182","author":"van der Fits","year":"2009","journal-title":"J. Immunol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/s0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B137","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.","volume":"76","author":"Van Der Heijde","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B138","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/s0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial.","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"B139","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","article-title":"Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases.","volume":"191","author":"Van Rompaey","year":"2013","journal-title":"J. Immunol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1136\/annrheumdis-2016-210233","article-title":"An induction or flare of arthritis and\/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series.","volume":"76","author":"Varkas","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B141","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1002\/art.39282","article-title":"Review: animal models as a tool to dissect pivotal pathways driving spondyloarthritis.","volume":"67","author":"Vieira-Sousa","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system.","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/ng.493","article-title":"The imprinted DLK1-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes.","volume":"42","author":"Wallace","year":"2010","journal-title":"Nat. Genet."},{"key":"B144","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.semcdb.2008.07.020","article-title":"The JAK kinases: not just another kinase drug discovery target.","volume":"19","author":"Wilks","year":"2008","journal-title":"Semin. Cell Dev. Biol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.4049\/jimmunol.1400205","article-title":"Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23\/IL-17 axis.","volume":"193","author":"Works","year":"2014","journal-title":"J. Immunol."},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111728","article-title":"Tyk2: an upstream kinase of stats in cancer.","volume":"11","author":"W\u00f6ss","year":"2019","journal-title":"Cancers"},{"key":"B147","doi-asserted-by":"publisher","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine Kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165.","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J. Med. Chem."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.bbrc.2003.09.140","article-title":"SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor \u03b22 subunit.","volume":"310","author":"Yamamoto","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B149","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.4049\/jimmunol.166.9.5720","article-title":"A Heritable defect in IL-12 signaling in B10.Q\/J mice. ii. effect on acute resistance to toxoplasma gondii and rescue by IL-18 treatment.","volume":"166","author":"Yap","year":"2001","journal-title":"J. Immunol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","article-title":"Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry.","volume":"20","author":"Zhang","year":"2019","journal-title":"Nat. Immunol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2799-2","article-title":"A STAT3 palmitoylation cycle promotes TH17 differentiation and colitis.","volume":"586","author":"Zhang","year":"2020","journal-title":"Nature"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2021.685280\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T17:05:54Z","timestamp":1699203954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2021.685280\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":151,"alternative-id":["10.3389\/fgene.2021.685280"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2021.685280","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"article-number":"685280"}}